8 [45] M. D. Scheiber, K. D. R. Setchell, J. H. Liu, et al., “Dietary soy supplementation reduces LDL-oxidation and bone turnover in healthy postmenopausal women,” in Proceedings of the Endocrine Society Meeting, San Diego, Calif, USA, 1999. [46] B. H. Arjmandi, D. A. Khalil, E. A. Lucas, et al., “Soy protein with its isoﬂavones improves bone markers in middle-aged and elderly women,” FASEB Journal, vol. 15, article 728, 2000. [47] D.-F. Ma, L.-Q. Qin, P.-Y. Wang, and R. Katoh, “Soy isoﬂavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomizedcon- trolled trials,” European Journal of Clinical Nutrition, vol. 62, no. 2, pp. 155–161, 2008. [48] E. M. Choi, K. S. Suh, Y. S. Kim, et al., “Soybean ethanol extract increases the function of osteoblastic MC3T3-E1 cells,” Phytochemistry, vol. 56, pp. 733–739, 2001. [49] A. Atmaca, M. Kleerekoper, M. Bayraktar, and O. Kucuk, “Soy isoﬂavones in the management of postmenopausal osteoporosis,” Menopause, vol. 15, no. 4, pp. 748–757, 2008. [50] E. Romagnoli, S. Minisola, V. Carnevale, et al., “Eﬀect of estrogen deﬁciency on IGF-I plasma levels: relationship with bone mineral density in perimenopausal women,” Calciﬁed Tissue International, vol. 53, no. 1, pp. 1–6, 1993. [51] M. Nasu, T. Sugimoto, M. Chihara, M. Hiraumi, F. Kurimoto, and K. Chihara, “Eﬀect of natural menopause on serum levels of IGF-I and IGF-binding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women,” European Journal of Endocrinology, vol. 136, no. 6, pp. 608–616, 1997. [52] S. Boonen, E. Lesaﬀre, J. Dequeker, et al., “Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss,” Journal of the American Geriatrics Society, vol. 44, no. 11, pp. 1301–1306, 1996. [53] D.-F. Ma, L.-Q. Qin, P.-Y. Wang, and R. Katoh, “Soy isoﬂavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials,” Clinical Nutrition, vol. 27, no. 1, pp. 57–64, 2008. [54] M. Gambacciani, A. Spinetti, L. Piaggesi, et al., “Ipriﬂavone prevents the bone mass reduction in premenopausal women treated with gonadotropln hormone-releasing hormone ago- nists,” Bone and Mineral, vol. 26, no. 1, pp. 19–26, 1994. [55] C. Gennari, “Eﬀect of ipriﬂavone—a synthetic derivative of natural isoﬂavones—on bone mass loss in the early years after menopause,” Menopause, vol. 5, no. 1, pp. 9–15, 1998. [56] H. Ohta, S. Komukai, K. Makita, T. Masuzawa, and S. Nozawa, “Eﬀects of 1-year ipriﬂavone treatment on lumbar bone min- eral density and bone metabolic markers in postmenopausal women with low bone mass,” Hormone Research, vol. 51, no. 4, pp. 178–183, 1999. [57] L. Pagano, L. Teoﬁli, L. Mele, et al., “Oral ipriﬂavone (7- isopropoxy-isoﬂavone) treatment for elderly patients with resistant acute leukemias,” Annals of Oncology, vol. 10, no. 1, pp. 124–125, 1999. [58] Y. Sato, H. Kuno, M. Kaji, N. Saruwatari, and K. Oizumi, “Eﬀect of ipriﬂavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D,” American Journal of Physical Medicine and Rehabilitation, vol. 78, no. 5, pp. 457–463, 1999. [59] Y. Somekawa, M. Chiguchi, T. Ishibashi, K. Wakana, and T. Aso, “Eﬃcacy of ipriﬂavone in preventing adverse eﬀects of leuprolide,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 7, pp. 3202–3206, 2001. Journal of Osteoporosis [60] D. Agnusdei and L. Bufalino, “Eﬃcacy of ipriﬂavone in established osteoporosis and long-term safety,” Calciﬁed Tissue International, vol. 61, supplement 1, pp. S23–S27, 1997. [61] J. Y. Reginster, “Ipriﬂavone multicenter european fracture study. Ipriﬂavone in the treatment of postmenopausal osteo- porosis: a randomized controlled trial,” Journal of the Ameri- can Medical Association, vol. 285, no. 11, pp. 1482–1488, 2001. [62] P. Alexandersen, A. Toussaint, C. Christiansen, et al., “Ipri- ﬂavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial,” Journal of the American Medical Association, vol. 285, no. 11, pp. 1482–1488, 2001.